|Bid||41.53 x 3000|
|Ask||41.55 x 3000|
|Day's range||41.08 - 41.97|
|52-week range||39.14 - 55.00|
|Beta (5Y monthly)||0.54|
|PE ratio (TTM)||6.09|
|Forward dividend & yield||1.91 (4.67%)|
|Ex-dividend date||19 May 2022|
|1y target est||N/A|
Robust performances across the U.S. pharmacy and retail business are likely to have contributed to Walgreens' (WBA) Q3 performance.
Walgreens Boots Alliance Inc agreed to pay $105 million to settle a long-running class-action lawsuit accusing it of misleading shareholders about how rising generic drug prices and reimbursement pressures would hurt its pharmacy business. The preliminary all-cash settlement was filed on Thursday in a federal court in Chicago following six months of mediation, and requires a judge's approval. Walgreens denied wrongdoing, but settled to avoid the uncertainty, burden and cost of further litigation, settlement papers show.
Walgreens Boots Alliance (WBA) closed at $40.89 in the latest trading session, marking a +1.09% move from the prior day.